MiMedx still a top pick, says Canaccord Canaccord reiterated its Buy rating and top pick designation for MiMedx following the company's raised guidance. The firm believes fundamentals are in place to drive execution in wound care for the foreseeable future as the company's increase in sales force remains ahead of plan and reimbursement changes support growth and increased expectations. Canaccord has a $12 price target on the stock.
Piper Jaffray and the Alliance for Regenerative Medicine co-host conference 3rd Annual Regenerative Medicine Investor Day is being held in New York on March 25 with webcasted company presentations to begin at 8 am; not all company presentations may be webcasted. Webcast Link